Turquoise Biotechnologies

Executive Summary

Turquoise Biotechnologies is an Australian preclinical biotech pioneering exosome-based drug delivery for oncology, autoimmune, and other diseases. Its proprietary platforms—ExoAim, ExoMed, and ExoGene—enable targeted delivery of small molecules, RNA, DNA, and CRISPR components to specific cells and organs. Founded in 2018 and based in Sydney, the company operates with 10-50 employees and has not disclosed funding or valuation. The exosome delivery space is gaining traction due to its ability to overcome biological barriers and reduce off-target effects, positioning Turquoise as a potential leader if its platforms demonstrate efficacy and safety in vivo. However, being preclinical and privately held, the company’s progress is opaque, and it faces competition from established players in extracellular vesicle therapeutics. Key risks include manufacturing scale-up, immunogenicity, and regulatory hurdles. Despite these challenges, the versatility of its platforms across multiple therapeutic areas offers significant upside. The company’s current valuation is estimated, reflecting limited public information.

Upcoming Catalysts (preview)

• Q1 2027Completion of key preclinical studies in oncology models70% success
• Q4 2027IND or CTA filing for lead exosome therapeutic candidate50% success
• Q2 2027Series A funding round or strategic partnership60% success